MultiStem
Phase 2Small molecule
MultiStem is one of 3 small molecule programs targeting Systemic Inflammatory Response Syndrome. It is currently in Phase 2.
1
Indications
7
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Systemic Inflammatory Response Syndrome
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Januvia
ZZydus Therapeutics Inc.
Preclinical
MultiStem
HHealios K.K.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ischemic stroke2 trials
Acute Respiratory Distress Syndrome1 trial
Myeloid Leukemia1 trial
Liver Transplant1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MultiStem. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHealios K.K.